Plasma proteomic biomarkers identify non-responders and reveal biological insights about...

[Free GPT-4]
[PDF] nih.gov

Immune responses in checkpoint myocarditis across heart, blood and tumour

SM Blum, DA Zlotoff, NP Smith, IJ Kernin, S Ramesh… - Nature, 2024 - nature.com
Immune checkpoint inhibitors are widely used anticancer therapies that can cause morbid
and potentially fatal immune-related adverse events such as immune-related myocarditis …
Guardar Citar Citado por 5 Artículos relacionados Las 5 versiones
[Free GPT-4]
[HTML] nih.gov

[HTML][HTML] Prognostic value of von Willebrand factor levels in patients with metastatic melanoma treated by immune checkpoint inhibitors

JC Stadler, L Keller, C Mess, AT Bauer… - … for Immunotherapy of …, 2023 - ncbi.nlm.nih.gov
Background An increased incidence of thrombotic complications associated with an
increased mortality rate has been observed under immune checkpoint inhibition (ICI) …
Guardar Citar Citado por 9 Artículos relacionados Las 5 versiones
[Free GPT-4]
[HTML] medrxiv.org

Sequential pembrolizumab cooperates with platinum/5FU to remodel the tumor microenvironment in advanced gastric cancer: a phase II chemoimmunotherapy trial

M An, A Mehta, BH Min, YJ Heo, M Parikh, L Bi… - medRxiv, 2023 - medrxiv.org
Adding anti-PD1 antibodies to 5-FU/platinum chemotherapy improves survival in a subset of
advanced gastroesophageal adenocarcinoma (GEA) patients. Beyond PD-L1 expression …
Guardar Citar Citado por 2 Artículos relacionados En caché
[Free GPT-4]
[PDF] researchsquare.com

Sequential pembrolizumab cooperates with platinum/5FU to remodel the tumor immune microenvironment in advanced gastric cancer: a phase II …

S Klempner, J Lee, A Mehta, M An, BH Min, YJ Heo… - 2023 - researchsquare.com
Adding anti-PD1 antibodies to 5-FU/platinum chemotherapy improves survival in a subset of
advanced gastroesophageal adenocarcinoma (GEA) patients. Beyond PD-L1 expression …
Guardar Citar Citado por 1 Artículos relacionados Las 2 versiones Versión en HTML
[Free GPT-4]
[PDF] hal.science

Bloquer le TNF en combinaison avec les inhibiteurs de point de contrôle immunitaire pour traiter le mélanome avancé

M Virazels - 2023 - theses.hal.science
Les inhibiteurs de point de contrôle immunitaire (ICI) ont révolutionné la prise en charge des
patients atteints de mélanome avancé. Cependant la plupart souffrent d'effets indésirables …
Guardar Citar Artículos relacionados Búsqueda de bibliotecas Versión en HTML